Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 132

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Uptake Rates for Breast Cancer Genetic Testing: A Systematic Review

Ropka, Mary E., Wenzel, Jennifer, Phillips, Elayne K., Siadaty, Mir, Philbrick, John T. · 2006 · Cancer Epidemiology, Biomarkers & Prevention

Abstract

Purpose: Individuals and families dealing with the possibility of hereditary cancer risk face numerous decisions, including whether to obtain genetic testing. The purpose of this article is to determine what is known about the rate at which people obtain cancer genetic testing. Methods: Using MEDLINE, CINAHL, and PSYCHINFO plus reviewing reference lists of relevant articles, we identified 40 studies in May 2002 that addressed breast cancer–related decisions, enrolled adult participants, were published in 1990 or more recently, were peer-reviewed primary clinical studies, addressed genetic testing either alone or in combination with genetic counseling, and reported rates at which participants showed interest in and/or underwent cancer genetic testing. Information regarding study design, participants, and genetic testing uptake rates was recorded. Each article was reviewed for methodologic quality using a flexible quality review system applicable to all study types. Results: Of the 40 studies, 25 provided information about hypothetical genetic testing decisions, 14 about real decisions, and 1 about both. Mean hypothetical uptake was 66% (range, 20-96%) and real uptake was 59% (range, 25-96%). Multivariate logistic regression analyses found that decision type (real/hypothetical), personal and family history of breast cancer, and variability in sampling strategy, recruitment setting, and criteria for real and hypothetical uptake were independently associated with uptake. Our systematic review identified additional explanations for uptake variability (investigator influences, small sample sizes, variability in target populations, lack of clearly described sampling strategies, sampling methods open to bias, and variability in reporting associated risk factors). Conclusion: In addition to clinical characteristics, research methodologic issues are likely to be major determinants of variability in published breast cancer genetic testing uptake rates. An understanding of these issues will clarify to clinicians why their clinical experience may not be congruent with published rates and help guide future research. (Cancer Epidemiol Biomarkers Prev 2006;15(5):840–55)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-05-0002

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 71

  1. O'Connor AM, Legare F, Stacey D. Risk communication in practice: the contribution of decision aids. BMJ 2003;327:736–40. · DOI · Paper page
  2. O'Connor AM, Llewellyn-Thomas HA, Flood AB. Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff (Millwood) 2004;Suppl Web Exclusive: VAR 63–72. · DOI · Paper page
  3. Wennberg J. Unwarranted variations in healthcare delivery: implications for academic medical centres. BMJ 2002;325:961–4. · DOI · Paper page
  4. O'Connor AM, Mulley AG, Wennberg JE. Standard consultations are not enough to ensure decision quality regarding preference-sensitive options. J Natl Cancer Inst 2003;95:570–1. · doi:10.1093/jnci/95.8.570
  5. Briss P, Rimer B, Reilley B, et al. Promoting informed decisions about cancer screening in communities and healthcare systems. Am J Prev Med 2004;26:67–80. · DOI · Paper page
  6. Wang C, Gonzalez R, Marajver SD. Assessment of genetic testing and related counseling services: current research and future directions. Soc Sci Med 2004;58:1427–42. · DOI
  7. Calzone KA, Biesecker BB. Genetic testing for cancer predisposition. Cancer Nurs 2002;25:15–25; quiz 6–7. · DOI
  8. Press NA, Yasui Y, Reynolds S, Durfy SJ, Burke W. Women's interest in genetic testing for breast cancer susceptibility may be based on unrealistic expectations. Am J Med Genet 2001;99:99–110. · DOI
  9. Forrest K, Simpson SA, Wilson BJ, et al. To tell or not to tell: barriers and facilitators in family communication about genetic risk. Clin Genet 2003;64:317–26. · DOI · Paper page
  10. Bowen DJ, Bourcier E, Press N, Lewis FM, Burke W. Effects of individual and family functioning on interest in genetic testing. Community Genet 2004;7:25–32. · DOI
  11. McGivern B, Everett J, Yager GG, Baumiller RC, Hafertepen A, Saal HM. Family communication about positive BRCA1 and BRCA2 genetic test results. Genet Med 2004;6:503–9. · DOI
  12. Van Riper M, McKinnon WC. Genetic testing for breast and ovarian cancer susceptibility: a family experience. J Midwifery Womens Health 2004;49:210–9. · DOI
  13. McInerney-Leo A, Biesecker BB, Hadley DW, et al. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships. Am J Med Genet A 2005;133:165–9. · DOI
  14. Braithwaite D, Emery J, Walter F, Prevost AT, Sutton S. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2004;96:122–33. · DOI · Paper page
  15. Broadstock M, Michie S, Marteau T. Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 2000;8:731–8. · DOI · Paper page
  16. Meiser B, Halliday JL. What is the impact of genetic counselling in women at increased risk of developing hereditary breast cancer? A meta-analytic review. Soc Sci Med 2002;54:1463–70. · DOI · Paper page
  17. Butow PN, Lobb EA, Meiser B, Barratt A, Tucker KM. Psychological outcomes and risk perception after genetic testing and counselling in breast cancer: a systematic review. [Review] [26 refs]. Med J Aust 2003;178:77–81. · DOI · Paper page
  18. Shaw C, Abrams K, Marteau TM. Psychological impact of predicting individuals' risks of illness: a systematic review. Soc Sci Med 1999;49:1571–98. · DOI · Paper page
  19. Vadaparampil ST, Ropka M, Stefanek ME. Measurement of psychological factors associated with genetic testing for hereditary breast, ovarian, and colon cancers. Fam Cancer 2005;4:195–206. · DOI
  20. Lee RC, Kmet L, Cook LS, Lorenzetti D, Godlovitch G, Einsiedel E. Risk assessment for inherited susceptibility to cancer: a review of the psychosocial and ethical dimensions. Genet Test 2005;9:66–79. · DOI
  21. Miller SM, Bowen DJ, Campbell MK, et al. Current research promises and challenges in behavioral oncology: report from the American Society of Preventive Oncology annual meeting, 2002. Cancer Epidemiol Biomarkers Prev 2004;13:171–80. · DOI
  22. Bowen D, Patenaude AF, Vernon SW. Psychosocial issues in cancer genetics: from the laboratory to the public. Cancer Epidemiol Biomarkers Prev 1999;8:326–8.
  23. Feetham SL, Thomson EJ, Hinshaw AS. Nursing leadership in genomics for health and society. J Nurs Scholarsh 2005;37:102–10. · DOI
  24. Gwyn K, Vernon SW, Conoley PM. Intention to pursue genetic testing for breast cancer among women due for screening mammography. Cancer Epidemiol Biomarkers Prev 2003;12:96–102.
  25. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 1994;12:843–50. · DOI · Paper page
  26. Lerman C, Seay J, Balshem A, Audrain J. Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet 1995;57:385–92. · DOI · Paper page
  27. Struewing JP, Lerman C, Kase RG, Giambarresi TR, Tucker MA. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev 1995;4:169–73.
  28. Andrykowski MA, Munn RK, Studts JL. Interest in learning of personal genetic risk for cancer: a general population study. Prev Med 1996;25:527–36. · DOI
  29. De Wit ACD, Tibben A, Frets PG, Meijers-Heijboer EJ, Devilee P, Niermeijer MF. Males at-risk for the BRCA1-gene, the psychological impact. Psychooncology 1996;5:251–7. · doi:10.1002/(sici)1099-1611(199609)5:3<251::aid-pon225>3.0.co;2-6
  30. Julian-Reynier C, Eisinger F, Vennin P, et al. Attitudes towards cancer predictive testing and transmission of information to the family. J Med Genet 1996;33:731–6. · DOI
  31. Patenaude AF, Schneider KA, Kieffer SA, et al. Acceptance of invitations for p53 and BRCA1 predisposition testing: factors influencing potential utilization of cancer genetic testing. Psychooncology 1996;5:241–50. · DOI
  32. Watson M, Lloyd SM, Eeles R, et al. Psychosocial impact of testing (by linkage) for the BRCA1 breast cancer gene: an investigation of two families in the research setting. Psychooncology 1996;5:233–9. · doi:10.1002/(sici)1099-1611(199609)5:3<233::aid-pon238>3.0.co;2-t
  33. Bernhardt BA, Geller G, Strauss M, et al. Toward a model informed consent process for BRCA1 testing: a qualitative assessment for women's attitudes. J Genet Couns 1997;6:207–22. · DOI
  34. Jacobsen PB, Valdimarsdottir HB, Brown KL, Offit K. Decision-making about genetic testing among women at familial risk for breast cancer. Psychosom Med 1997;59:459–66. · DOI · Paper page
  35. Lerman C, Biesecker B, Benkendorf JL, et al. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst 1997;89:148–57. · DOI · Paper page
  36. Tambor ES, Rimer BK, Strigo TS. Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. Am J Med Genet 1997;68:43–9. · doi:10.1002/(sici)1096-8628(19970110)68:1<43::aid-ajmg8>3.0.co;2-z
  37. Braczkowski R, Nowakowska-Zajdel E, Zubelewicz B, Muc-Wierzgon M, Romanowski W. Genetic testing for breast cancer susceptibility: Polish women's attitudes. J Exp Clin Cancer Res 1998;17:299–302.
  38. Mogilner A, Otten M, Cunningham JD, Brower ST. Awareness and attitudes concerning BRCA gene testing. Ann Surg Oncol 1998;5:607–12. · DOI
  39. Bluman LG, Rimer BK, Berry DA, et al. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol 1999;17:1040–6. · doi:10.1200/jco.1999.17.3.1040
  40. Cappelli M, Surh L, Humphreys L, et al. Psychological and social determinants of women's decisions to undergo genetic counseling and testing for breast cancer. Clin Genet 1999;55:419–30. · DOI
  41. Durfy SJ, Bowen DJ, McTiernan A, Sporieder J, Burke W. Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington. Cancer Epidemiol Biomarkers Prev 1999;8:369–75.
  42. Lipkus IM, Iden D, Terrenoire J, Feaganes JR. Relationships among breast cancer concern, risk perceptions, and interest in genetic testing for breast cancer susceptibility among African-American women with and without a family history of breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8:533–9.
  43. Ludman EJ, Curry SJ, Hoffman E, Taplin S. Women's knowledge and attitudes about genetic testing for breast cancer susceptibility. Eff Clin Pract 1999;2:158–62.
  44. Ryan EL, Skinner CS. Risk beliefs and interest in counseling: focus-group interviews among first-degree relatives of breast cancer patients. J Cancer Educ 1999;14:99–103.
  45. Smith KR, West JA, Croyle RT, Botkin JR. Familial context of genetic testing for cancer susceptibility: moderating effect of sibling's test results on psychological distress one to two weeks after BRCA1 mutation testing. Cancer Epidemiol Biomarkers Prev 1999;8:385–92.
  46. Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B. Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 2000;9:1251–4.
  47. Biesecker BB, Ishibe N, Hadley DW, et al. Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. Am J Med Genet 2000;93:257–63. · doi:10.1002/1096-8628(20000814)93:4<257::aid-ajmg1>3.0.co;2-8
  48. Bosompra K, Flynn BS, Ashikaga T, Rairikar CJ, Worden JK, Solomon LJ. Likelihood of undergoing genetic testing for cancer risk: a population-based study. Prev Med 2000;30:155–66. · DOI
  49. Broadstock M, Michie S, Gray J, Mackay J, Marteau TM. The psychological consequences of offering mutation searching in the family for those at risk of hereditary breast and ovarian cancer-a pilot study. Psychooncology 2000;9:537–48. · DOI
  50. Burke W, Culver JO, Bowen D, et al. Genetic counseling for women with an intermediate family history of breast cancer. Am J Med Genet 2000;90:361–8. · DOI
  51. Julian-Reynier C, Sobol H, Sevilla C, Nogues C, Bourret P. Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network. Psychooncology 2000;9:504–10. · doi:10.1002/1099-1611(200011/12)9:6<504::aid-pon491>3.0.co;2-r
  52. Phillips KA, Warner E, Meschino WS, et al. Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. Clin Genet 2000;57:376–83. · DOI
  53. Schwartz MD, Hughes C, Roth J, et al. Spiritual faith and genetic testing decisions among high-risk breast cancer probands. Cancer Epidemiol Biomarkers Prev 2000;9:381–5.
  54. Wood ME, Mullineaux L, Rahm AK, Fairclough D, Wenzel L. Impact of BRCA1 testing on women with cancer: a pilot study. Genet Test 2000;4:265–72. · DOI
  55. Cappelli M, Surh L, Walker M, et al. Psychological and social predictors of decisions about genetic testing for breast cancer in high-risk women. Psychol Health Med 2001;6:321–33. · doi:10.1080/1354850012005436
  56. Schwartz MD, Benkendorf J, Lerman C, Isaacs C, Ryan-Robertson A, Johnson L. Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2. Cancer 2001;92:932–40. · DOI
  57. Velicer CM, Taplin S. Genetic testing for breast cancer: where are health care providers in the decision process? Genet Med 2001;3:112–9. · doi:10.1097/00125817-200103000-00005
  58. Bottorff JL, Ratner PA, Balneaves LG, et al. Women's interest in genetic testing for breast cancer risk: the influence of sociodemographics and knowledge. Cancer Epidemiol Biomarkers Prev 2002;11:89–95.
  59. Clark S, Bluman LG, Borstelmann N, et al. Patient motivation, satisfaction, and coping in genetic counseling and testing for BRCA1 and BRCA2. J Genet Couns 2000;9:219–35. · DOI
  60. Lee SC, Bernhardt BA, Helzlsouer KJ. Utilization of BRCA1/2 genetic testing in the clinical setting: report from a single institution. Cancer 2002;94:1876–85. · DOI
  61. Peterson EA, Milliron KJ, Lewis KE, Goold SD, Merajver SD. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 2002;11:79–87.
  62. Green MJ, Biesecker BB, McInerney AM, Mauger D, Fost N. An interactive computer program can effectively educate patients about genetic testing for breast cancer susceptibility. Am J Med Genet 2001;103:16–23. · DOI
  63. Brain K, Norman P, Gray J, Rogers C, Mansel R, Harper P. A randomized trial of specialist genetic assessment: psychological impact on women at different levels of familial breast cancer risk. Br J Cancer 2002;86:233–8. · doi:10.1038/sj.bjc.6600051
  64. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group. Br J Surg 2000;87:1448–54. · DOI · Paper page
  65. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–12. · DOI · Paper page
  66. Siadaty MS, Shu J. Proportional odds ratio model for comparison of diagnostic tests in meta-analysis. BMC Med Res Methodol 2004;4:27. · DOI
  67. Siadaty MS, Philbrick J, Heim SW, Schectman JM. Repeated-measures modeling improved comparison of diagnostic tests in meta-analysis of dependent studies. J Clin Epidemiol 2004;57:698–710. · doi:10.1016/j.jclinepi.2003.12.007
  68. Patenaude AF. The genetic testing of children for cancer susceptibility: ethical, legal, and social issues. Behav Sci Law 1996;14:393–410. · doi:10.1002/(sici)1099-0798(199623)14:4<393::aid-bsl248>3.0.co;2-9
  69. Brain K, Gray J, Norman P, et al. Randomized trial of a specialist genetic assessment service for familial breast cancer. J Natl Cancer Inst 2000;92:1345–51.
  70. Brooks L, Lennard F, Shenton A, et al. BRCA 1/2 predictive testing: a study of uptake in two centres. Eur J Hum Genet 2004;12:654–62. · doi:10.1038/sj.ejhg.5201206
  71. Bottorff JL, Ratner PA, Richardson C, et al. The influence of question wording on assessments of interest in genetic testing for breast cancer risk. Psychooncology 2003;12:720–8. · DOI

Cited by

See all 132

Metadata

Authors
Ropka, M. E., Wenzel, J., Phillips, E. K., Siadaty, M., & Philbrick, J. T.
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2006-05-01
Volume
15
Issue
5
Pages
840-855
ISSN
  • 1055-9965
  • 1538-7755
Cited by
132
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Uptake Rates for Breast Cancer Genetic Testing: A Systematic Review. https://app.cochat.ai/papers/10.1158/1055-9965.epi-05-0002
The paper
Ropka, M. E., Wenzel, J., Phillips, E. K., Siadaty, M., & Philbrick, J. T. (2006). Uptake Rates for Breast Cancer Genetic Testing: A Systematic Review. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-05-0002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.